Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study | Sleep Review
Alkermes’ alixorexton met primary and key secondary endpoints in a phase 2 trial for narcolepsy type 1, showing dose-dependent improvements.| Sleep Review
